0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover193.02%IV-103.46%PremiumSep 20, 2024Expiry Date10.17Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8678Delta0.0441Gamma0.95Leverage Ratio-0.0187Theta-0.0091Rho-0.82Eff Leverage0.0057Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics reported strong Q2 2024 financial results, with net product revenues of $30.9M for the ZORYVE franchise, representing a 547% increase year-over-year and 43% growth quarter-over-quarter. The company saw improved gross-to-net (GTN) margins, now in the high 50% range. Arcutis entered a co-promotion agreement with Kowa Pharmaceuticals to expand ZORYVE's reach in primary care and pediatric offices. They also submitted an sNDA for ZORYV...
Larger Image: tradingview.com...
$Arcutis Biotherapeutics (ARQT.US)$
No comment yet